Abbott Laboratories $ABT Shares Bought by Annex Advisory Services LLC

Annex Advisory Services LLC raised its position in Abbott Laboratories (NYSE:ABT) by 11.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 87,004 shares of the healthcare product maker’s stock after buying an additional 8,950 shares during the quarter. Annex Advisory Services LLC’s holdings in Abbott Laboratories were worth $10,901,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Capital International Investors grew its stake in shares of Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Abbott Laboratories by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the last quarter. Invesco Ltd. grew its stake in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after acquiring an additional 4,713,135 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Abbott Laboratories by 3.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after acquiring an additional 499,351 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in Abbott Laboratories by 7.2% in the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after acquiring an additional 864,531 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.4%

Shares of ABT stock opened at $101.06 on Wednesday. The firm has a market cap of $176.01 billion, a P/E ratio of 27.17, a PEG ratio of 1.61 and a beta of 0.79. Abbott Laboratories has a 1-year low of $99.05 and a 1-year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The firm’s 50-day simple moving average is $108.59 and its 200-day simple moving average is $119.30.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Oppenheimer lowered their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Piper Sandler reduced their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Finally, Argus reduced their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $134.58.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.